These diabetes stocks, pummeled by the Ozempic craze, now look like bargains, analysts say

  • 📰 MarketWatch
  • ⏱ Reading Time:
  • 53 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 25%
  • Publisher: 97%

Business News News

Business Business Latest News,Business Business Headlines

DexCom could be the first stock to break out of ‘GLP jail,’ analysts say, as market continues to punish device makers

Diabetes device stocks that have been crushed in recent months by an Ozempic-fueled weight-loss drug frenzy have now been punished enough, some analysts say.

The negativity has been driven largely by the concern that widespread use of GLP-1 drugs like Ozempic and Wegovy will mean less insulin use and more stable blood glucose levels among type 2 diabetes patients, shrinking the market for diabetes devices.

The GLP-1 drugs aren’t as catastrophic for device makers as the share price declines would suggest, some analysts say, in part because the type 1 diabetes market is relatively insulated from the GLP-1 effects, and there’s still plenty of room for growth in the type 2 diabetes market, even as more of these patients start taking Mounjaro and similar treatments.

The pullback in DexCom shares “represents a good buying opportunity,” Oppenheimer analysts wrote in a mid September report, saying use of continuous glucose monitoring should continue to increase. Raymond James analysts also wrote in a mid September report that DexCom is their favorite diabetes play, as continuous glucose monitoring “can cohabitate with GLP-1s” and upward revenue revisions can still drive the stock.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 3. in BUSİNESS

Business Business Latest News, Business Business Headlines